WVE WAVE Life Sciences

Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022

Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, November 10, 2022, to discuss the company’s third quarter 2022 financial results and provide a business update.

The webcast of the conference call may be accessed by visiting “Events” at the investor relations section of the Wave Life Sciences corporate website: .

Participants planning to ask a question during the Q&A portion of the live call can join the webcast at the following audio conferencing link: .

Following the conference call, an archived version of the call will be available on the website.

About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit and follow Wave on Twitter .



Investor Contact:

Kate Rausch

617-949-4827

Media Contact:

Alicia Suter

617-949-4817



EN
03/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WAVE Life Sciences

ResearchPool Subscriptions

Get the most out of your insights

Get in touch